Rabies virus - Pipeline Insight, 2021
This report can be delivered to the clients within 48-72 Hours
DelveInsight’s, “Rabies virus - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Rabies virus pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Rabies virus: Overview
Rabies is a viral zoonotic disease that is transmitted to human beings through the bite of rabid animals. The virus predominantly infects the central nervous system leading to progressive and fatal inflammation of brain and spinal cord. Rabies is estimated to cause death of more than 59,000 individuals over 150 countries across the globe with most of the cases in Africa, and Asia. Rabies infection cannot be diagnosed easily as there is no usual way to confirm rabies transmission at the time of bite. Therefore, prophylactic treatment is initiated without waiting for confirm diagnosis. If left untreated may lead to coma or death.
“Rabies virus - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Rabies virus pipeline landscape is provided which includes the disease overview and Rabies virus treatment guidelines. The assessment part of the report embraces, in depth Rabies virus commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Rabies virus collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Rabies virus R&D. The therapies under development are focused on novel approaches to treat/improve Rabies virus.
Rabies virus Emerging Drugs Chapters
This segment of the Rabies virus report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Rabies virus Emerging Drugs
SYN-023: Synermore Biologics
Synermore’s lead drug candidate, SYN-023, is a conglomerate of two anti-rabies humanized monoclonal antibodies CTB-011, and CTB-012. The drug binds to two different antigenic sites on rabies glycoprotein which results in virus neutralization in a similar mechanism by which immune response of the body neutralize the foreign antigen by producing antibodies. The drug has demonstrated good efficacy in its Phase I and Phase II trials. It has been designated with an orphan drug status for rabies.
PIKA adjuvant based rabies vaccine: Yisheng Biopharma
Yisheng’s “breakthrough” drug PIKA is an adjuvant based rabies vaccine which consist of biologic complexes that are agonist to TLR3, RIG-I, and MDA5 pathways. It is an analog of double stranded RNA that interacts with TLR3 when delivered with relevant protein based molecule. Phase I study of the molecule has demonstrated good safety and efficacy. Also, the drug has enhanced the humoral and cellular immunity.
Further product details are provided in the report……..
Rabies virus: Therapeutic Assessment
This segment of the report provides insights about the different Rabies virus drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Rabies virus
There are approx. 10+ key companies which are developing the therapies for Rabies virus. The companies which have their Rabies virus drug candidates in the most advanced stage, i.e. phase III include, Synermore Biologics.
Phases
DelveInsight’s report covers around 10+ products under different phases of clinical development like
Rabies virus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Rabies virus: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Rabies virus therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Rabies virus drugs.
Rabies virus Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Rabies virus - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Rabies virus pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Rabies virus: Overview
Rabies is a viral zoonotic disease that is transmitted to human beings through the bite of rabid animals. The virus predominantly infects the central nervous system leading to progressive and fatal inflammation of brain and spinal cord. Rabies is estimated to cause death of more than 59,000 individuals over 150 countries across the globe with most of the cases in Africa, and Asia. Rabies infection cannot be diagnosed easily as there is no usual way to confirm rabies transmission at the time of bite. Therefore, prophylactic treatment is initiated without waiting for confirm diagnosis. If left untreated may lead to coma or death.
“Rabies virus - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Rabies virus pipeline landscape is provided which includes the disease overview and Rabies virus treatment guidelines. The assessment part of the report embraces, in depth Rabies virus commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Rabies virus collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Rabies virus R&D. The therapies under development are focused on novel approaches to treat/improve Rabies virus.
Rabies virus Emerging Drugs Chapters
This segment of the Rabies virus report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Rabies virus Emerging Drugs
SYN-023: Synermore Biologics
Synermore’s lead drug candidate, SYN-023, is a conglomerate of two anti-rabies humanized monoclonal antibodies CTB-011, and CTB-012. The drug binds to two different antigenic sites on rabies glycoprotein which results in virus neutralization in a similar mechanism by which immune response of the body neutralize the foreign antigen by producing antibodies. The drug has demonstrated good efficacy in its Phase I and Phase II trials. It has been designated with an orphan drug status for rabies.
PIKA adjuvant based rabies vaccine: Yisheng Biopharma
Yisheng’s “breakthrough” drug PIKA is an adjuvant based rabies vaccine which consist of biologic complexes that are agonist to TLR3, RIG-I, and MDA5 pathways. It is an analog of double stranded RNA that interacts with TLR3 when delivered with relevant protein based molecule. Phase I study of the molecule has demonstrated good safety and efficacy. Also, the drug has enhanced the humoral and cellular immunity.
Further product details are provided in the report……..
Rabies virus: Therapeutic Assessment
This segment of the report provides insights about the different Rabies virus drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Rabies virus
There are approx. 10+ key companies which are developing the therapies for Rabies virus. The companies which have their Rabies virus drug candidates in the most advanced stage, i.e. phase III include, Synermore Biologics.
Phases
DelveInsight’s report covers around 10+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Rabies virus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Rabies virus: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Rabies virus therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Rabies virus drugs.
Rabies virus Report Insights
- Rabies virus Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Rabies virus drugs?
- How many Rabies virus drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Rabies virus?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Rabies virus therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Rabies virus and their status?
- What are the key designations that have been granted to the emerging drugs?
- Synermore Biologics
- CureVAC AG
- Yisheng Biopharma
- Sanofi Pasteur
- GlaxoSmithKline
- SYN-023
- CV7202
- PIKA
- Verorabvax
- GSK3903133A
Introduction
Executive Summary
Rabies virus: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Rabies virus – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Rabies virus companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Rabies virus Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
SYN 023: Synermore Biologics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
PIKA: Yisheng Biopharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Rabies virus Key Companies
Rabies virus Key Products
Rabies virus- Unmet Needs
Rabies virus- Market Drivers and Barriers
Rabies virus- Future Perspectives and Conclusion
Rabies virus Analyst Views
Rabies virus Key Companies
Appendix
Executive Summary
Rabies virus: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Rabies virus – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Rabies virus companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Rabies virus Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
SYN 023: Synermore Biologics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
PIKA: Yisheng Biopharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Rabies virus Key Companies
Rabies virus Key Products
Rabies virus- Unmet Needs
Rabies virus- Market Drivers and Barriers
Rabies virus- Future Perspectives and Conclusion
Rabies virus Analyst Views
Rabies virus Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Rabies virus
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Rabies virus
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Rabies virus
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Rabies virus
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
